Swollen lymph nodes serve as a crucial early warning system when the body fights HIV. These changes often appear subtle at first but persist beyond the duration of typical viral infections.
Mount Sinai researchers have developed a method to uncover the hidden immune cells that harbor the human immunodeficiency ...
Data from a very early-phase trial shows that the drug is safe and remains in the body for up to 56 weeks. From two ...
Gilead released data showing that an HIV drug, called lenacapavir, could provide virtually complete protection against ...
Offering mailed self-testing for HIV encouraged patients to test themselves for HIV but require methods of improving ...
Already, significant harm has been done to inhibit progress combating HIV/AIDS, and the next four years could return us to ...
Early diagnosis and prompt antiretroviral therapy initiation are critical for children due to the rapid progression of HIV in ...
Bay Area drug giant Gilead is plotting the trial of a groundbreaking, once-a-year HIV prevention drug lenacapavir.
Incidence assays for differentiating early from established HIV infection To understand the epidemiology of HIV, the incidence of infection must be estimated. Immunoassays for assessing prevalence ...
The company is planning a Phase 3 trial for the new formulation of lenacapavir, Stat reports. Other pharma and technology news is on microplastics and the spread of antibiotic-resistant superbugs; a ...
Study findings provide a new gene pathway for potential treatment of the virus affecting millions. Mount Sinai researchers have developed a method to uncover the hidden immune cells that harbor ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results